Aptevo Therapeutics Inc. short interest in 2022
In 2022, Aptevo Therapeutics Inc.'s disclosed short interest ran from 3.03% of shares outstanding on 14 Jan 2022 to 1.02% on 30 Nov 2022, a change of -2.01 percentage points. The year's high was 4.03% on 31 Mar 2022 and its low 0.80% on 31 Aug 2022, averaging 2.23% across 21 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 5.41 days on 31 May 2022. Full history: Aptevo Therapeutics Inc..
Cite this page
By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2026
2022 in figures
- Start of year
- 3.03% (14 Jan 2022)
- End of year
- 1.02% (30 Nov 2022)
- Change
- -2.01 pp
- High
- 4.03% (31 Mar 2022)
- Low
- 0.80% (31 Aug 2022)
- Average
- 2.23%
- Highest days to cover
- 5.41 (31 May 2022)
- SEC filings marked
- 8
Every report in 2022
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 14 Jan 2022 | 3.03% | 1.27 | |
| 15 Feb 2022 | 3.61% | 1.00 | |
| 28 Feb 2022 | 2.91% | 1.70 | |
| 15 Mar 2022 | 2.95% | 1.29 | |
| 31 Mar 2022 | 4.03% | 1.00 | 10-K filed, results (8-K) |
| 14 Apr 2022 | 3.77% | 1.02 | |
| 29 Apr 2022 | 3.31% | 3.35 | |
| 13 May 2022 | 2.87% | 3.32 | 10-Q filed, results (8-K) |
| 31 May 2022 | 2.90% | 5.41 | |
| 15 Jun 2022 | 3.51% | 1.00 | |
| 30 Jun 2022 | 2.64% | 1.92 | |
| 15 Jul 2022 | 1.84% | 1.95 | |
| 29 Jul 2022 | 1.67% | 2.32 | |
| 15 Aug 2022 | 0.84% | 1.00 | 10-Q filed, results (8-K) |
| 31 Aug 2022 | 0.80% | 1.00 | |
| 15 Sep 2022 | 0.83% | 1.02 | |
| 30 Sep 2022 | 1.03% | 1.13 | |
| 14 Oct 2022 | 1.12% | 1.18 | |
| 31 Oct 2022 | 1.20% | 3.43 | |
| 15 Nov 2022 | 1.05% | 2.34 | 10-Q filed, results (8-K) |
| 30 Nov 2022 | 1.02% | 3.16 |
See also: Aptevo Therapeutics Inc.'s full history · most shorted US stocks of 2022 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.